We are a METI-approved technical research association dedicated to advancing the control of innate immunity. Our consortium unites universities, hospitals and industry to turn discoveries on lipopolysaccharide (LPS) and TLR4 signaling into practical impact.
We pursue rigorous science, open collaboration and translational outcomes across vaccines, inflammation control and safety assessment.
We pursue rigorous science, open collaboration and translational outcomes across vaccines, inflammation control and safety assessment.
We investigate how LPS structures tune TLR4–MD2 signaling and downstream innate pathways to modulate inflammation and adjuvanticity. Our platforms span chemical synthesis of lipid A/LPS analogs, receptor assays, transcriptomics, in vitro/in vivo models, and safety evaluation.
By integrating structural biology with systems immunology, we design ligands and strategies for precise immune control.
By integrating structural biology with systems immunology, we design ligands and strategies for precise immune control.
Work with us through joint or contract research, technical consulting, facilities access, and tailored training. We welcome early feasibility studies through to multi-year partnerships, with IP and publication plans aligned to your goals.
For collaboration and media inquiries, please use our English contact form. Our team will respond within 3–5 business days.